Medication info

Olmesartan Plus Tablet 20/12.5 mg

Prescription medicationOralExpired
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Kookje Pharmaceutical Co., Ltd.
Appearance
This medication is a round film-coated tablet that is light orange in color.
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Expired

MFDS item code 201100890 · Approved 2011.02.24

This product's status changed to Expired on 2024.07.01. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Before administering this medicine, it is recommended that the dosage of olmesartan medoxomil or hydrochlorothiazide be adjusted separately. If blood pressure is not adequately controlled with either individual component, administer 1 tablet of this medicine once daily, regardless of meals. Adjust the dose at intervals of 2~4 weeks based on the patient's blood pressure response. A marked reduction in blood pressure may occur when olmesartan medoxomil is added or patients are switched to this medicine (olmesartan medoxomil/hydrochlorothiazide) in patients taking high doses of hydrochlorothiazide alone, or in patients with volume depletion or hyponatremia. In such cases, the hydrochlorothiazide dose should be reduced to 12.5mg before olmesartan medoxomil is added. <Elderly patients> In elderly patients, start with the lowest dose and exercise caution when adjusting the dose, taking into consideration the patient's renal or cardiac function, comorbidities, and other concomitant medications. <Patients with renal impairment> This medicine (olmesartan medoxomil/hydrochlorothiazide) is generally administered to patients with mild to moderate renal impairment (creatinine clearance>30mL/min). This medicine (olmesartan medoxomil/hydrochlorothiazide) should not be administered to patients with more severe renal impairment, as loop diuretics are preferable to thiazide diuretics in these patients. <Patients with hepatic impairment> Use of this medicine is not recommended because there is no experience with its use in patients with hepatic impairment.
Child dose
<Pediatric patients> Safety▪efficacy in pediatric patients has not been established.

Ingredients

Manufacturer
Kookje Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication is used for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled with monotherapy of Olmesartan Medoxomil or Hydrochlorothiazide. It effectively lowers blood pressure and helps prevent complications caused by hypertension. It improves patient health through safe and sustained blood pressure control.

How to take

Adult dose

Before administering this medicine, it is recommended that the dosage of olmesartan medoxomil or hydrochlorothiazide be adjusted separately. If blood pressure is not adequately controlled with either individual component, administer 1 tablet of this medicine once daily, regardless of meals. Adjust the dose at intervals of 2~4 weeks based on the patient's blood pressure response. A marked reduction in blood pressure may occur when olmesartan medoxomil is added or patients are switched to this medicine (olmesartan medoxomil/hydrochlorothiazide) in patients taking high doses of hydrochlorothiazide alone, or in patients with volume depletion or hyponatremia. In such cases, the hydrochlorothiazide dose should be reduced to 12.5mg before olmesartan medoxomil is added. <Elderly patients> In elderly patients, start with the lowest dose and exercise caution when adjusting the dose, taking into consideration the patient's renal or cardiac function, comorbidities, and other concomitant medications. <Patients with renal impairment> This medicine (olmesartan medoxomil/hydrochlorothiazide) is generally administered to patients with mild to moderate renal impairment (creatinine clearance>30mL/min). This medicine (olmesartan medoxomil/hydrochlorothiazide) should not be administered to patients with more severe renal impairment, as loop diuretics are preferable to thiazide diuretics in these patients. <Patients with hepatic impairment> Use of this medicine is not recommended because there is no experience with its use in patients with hepatic impairment.

Child dose

<Pediatric patients> Safety▪efficacy in pediatric patients has not been established.

Precautions

This medication can cause serious harm to the fetus or newborn if administered to women during the second or third trimester of pregnancy, thus it should be discontinued immediately upon confirmation of pregnancy. Patients with allergies to any components of this medication or those with certain kidney diseases, liver diseases, or electrolyte imbalances should not use it. Patients with very low blood pressure or reduced blood volume should be closely monitored before starting this medication, and appropriate action should be taken immediately if symptoms of hypotension appear. Patients with impaired kidney function or those who have undergone kidney transplantation should have electrolytes and kidney function tested regularly while taking this medication. Patients with severely impaired liver function or certain heart diseases should exercise caution when using this medication. This medication may increase the risk of skin cancer, so it is essential to avoid sun exposure and consult a doctor immediately if any skin abnormalities occur. Dizziness or drowsiness may occur during treatment, therefore it's advisable to avoid driving or operating hazardous machinery. Interactions may occur when taken with other antihypertensive medications, diuretics, or potassium supplements, so patients should consult their doctor or pharmacist. This medication is not recommended for breastfeeding women, and if necessary, breastfeeding should be stopped or the medication should be discontinued. Safety in children has not been established, thus caution is required for use. In case of overdose, symptoms such as low blood pressure, electrolyte imbalance, and dehydration may occur, necessitating immediate medical treatment. For the elderly, it is safest to start at a low dose considering the decline in kidney and liver function.

Side effects

nausea, hyperuricemia, dizziness, upper respiratory tract infection, headache, urinary tract infection, chest pain, back pain, peripheral edema, vertigo, abdominal pain, dyspepsia, gastroenteritis, diarrhea, elevated AST, elevated GGT, elevated ALT, hyperlipidemia, elevated creatine phosphokinase, hyperglycemia, arthritis, arthralgia, myalgia, cough, rash, hematuria, facial edema, weakness, angioedema, anaphylactic reaction, vomiting, rhabdomyolysis, acute renal failure, increased serum creatinine, hair loss, itching, urticaria, hyponatremia, frequent urination, palpitations, headache, fatigue, drowsiness, emotional blunting, restlessness, interstitial pneumonia, pulmonary edema, acute respiratory distress syndrome, orthostatic hypotension, arrhythmia, temporary blurred vision, jaundice, hepatitis, acute cholecystitis, necrotizing vasculitis, facial flushing, photodermatosis, anaphylaxis, interstitial nephritis, renal dysfunction, lethargy, nasal congestion, erectile dysfunction, systemic lupus erythematosus exacerbation, hypercalcemia, muscle cramps, sensory disturbances, weakness, Stevens-Johnson syndrome, erythema multiforme, exfoliative dermatitis, toxic epidermal necrolysis, angioedema, chronic malabsorption syndrome, chronic diarrhea, elevated serum creatinine, elevated blood pressure, nosebleed, asthma

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture and is safely stored at room temperature between 1 and 25 degrees Celsius.

Appearance and packaging

Appearance

This medication is a round film-coated tablet that is light orange in color.

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.